UA75392C2 - N-substituted non-aryl heterocyclic antagonists nmda/nr2b - Google Patents

N-substituted non-aryl heterocyclic antagonists nmda/nr2b Download PDF

Info

Publication number
UA75392C2
UA75392C2 UA2003098659A UA2003098659A UA75392C2 UA 75392 C2 UA75392 C2 UA 75392C2 UA 2003098659 A UA2003098659 A UA 2003098659A UA 2003098659 A UA2003098659 A UA 2003098659A UA 75392 C2 UA75392 C2 UA 75392C2
Authority
UA
Ukraine
Prior art keywords
group
alkyl
hydroxy
pharmaceutically acceptable
trifluoromethyl
Prior art date
Application number
UA2003098659A
Other languages
English (en)
Ukrainian (uk)
Inventor
Cristopher F Klayborn
John U Butcher
David A Clairmon
Brayan E Libbi
Nigel G Liverton
Peter M Manson
Kevin T Nguyen
John A Mccoli
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23034191&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA75392(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of UA75392C2 publication Critical patent/UA75392C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
UA2003098659A 2001-02-23 2002-02-20 N-substituted non-aryl heterocyclic antagonists nmda/nr2b UA75392C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27110001P 2001-02-23 2001-02-23
PCT/US2002/005226 WO2002068409A1 (en) 2001-02-23 2002-02-20 N-substituted nonaryl-heterocyclic nmda/nr2b antagonists

Publications (1)

Publication Number Publication Date
UA75392C2 true UA75392C2 (en) 2006-04-17

Family

ID=23034191

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2003098659A UA75392C2 (en) 2001-02-23 2002-02-20 N-substituted non-aryl heterocyclic antagonists nmda/nr2b

Country Status (33)

Country Link
US (2) US7217716B2 (de)
EP (1) EP1379520B2 (de)
JP (1) JP4179879B2 (de)
KR (1) KR100849839B1 (de)
CN (1) CN100567293C (de)
AT (1) ATE324371T1 (de)
AU (1) AU2002252053B2 (de)
BG (1) BG108113A (de)
BR (1) BR0207526A (de)
CA (1) CA2438895A1 (de)
CZ (1) CZ20032258A3 (de)
DE (1) DE60210944T3 (de)
DK (1) DK1379520T3 (de)
EA (1) EA005974B1 (de)
EC (1) ECSP034744A (de)
EE (1) EE200300403A (de)
ES (1) ES2261658T3 (de)
GE (1) GEP20063741B (de)
HR (1) HRP20030669A2 (de)
HU (1) HUP0303258A3 (de)
IL (2) IL157254A0 (de)
IS (1) IS6902A (de)
MX (1) MXPA03007621A (de)
NO (1) NO20033732L (de)
NZ (1) NZ527365A (de)
PL (1) PL364625A1 (de)
PT (1) PT1379520E (de)
SI (1) SI1379520T1 (de)
SK (1) SK10542003A3 (de)
UA (1) UA75392C2 (de)
WO (1) WO2002068409A1 (de)
YU (1) YU64303A (de)
ZA (1) ZA200306159B (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1399160A4 (de) * 2001-06-12 2004-08-25 Merck & Co Inc Nr2b-rezeptor-antagonisten zur behandlung oder prävention von migräne
CA2469228A1 (en) * 2001-12-03 2003-06-12 Japan Tobacco Inc. Azole compound and medicinal use thereof
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
WO2003077656A1 (en) * 2002-03-15 2003-09-25 Ciba Specialty Chemicals Holding Inc. 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
EP1502916A4 (de) 2002-04-16 2006-05-31 Teijin Ltd Piperidinderivate mit ccr3-antagonismus
AU2003231360B2 (en) 2002-04-25 2008-12-11 Teijin Limited 4,4-disubstituted piperidine derivatives having CCR3 antagonism
JP2004315511A (ja) * 2003-03-31 2004-11-11 Taisho Pharmaceut Co Ltd Ｍｃｈ受容体アンタゴニスト
DE602004015610D1 (de) * 2003-06-04 2008-09-18 Merck & Co Inc 3-fluoro-piperidine als nmda/nr2b antagonisten
US7592360B2 (en) 2003-06-04 2009-09-22 Merck & Co., Inc. 3-fluoro-piperidines as NMDA/NR2B antagonists
EP1656372B1 (de) 2003-07-30 2013-04-10 Rigel Pharmaceuticals, Inc. 2,4-pyrimidindiamine derivate zur behandlung oder vorbeugung von autoimmunerkrankungen
JP5032851B2 (ja) 2004-02-03 2012-09-26 アストラゼネカ アクチボラグ キナゾリン誘導体
CN1993363A (zh) * 2004-08-03 2007-07-04 默克公司 1,3－二取代的杂芳基nmda/nr2b拮抗剂
WO2006027252A1 (en) * 2004-09-10 2006-03-16 Ucb Pharma, Sa Sigma receptor ligands
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
AU2006264649A1 (en) 2005-06-30 2007-01-11 Prosidion Limited GPCR agonists
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
WO2007071639A1 (en) * 2005-12-21 2007-06-28 Janssen Pharmaceutica N.V. Substituted pyrazinone derivatives as alpha2c-adrenoreceptor antagonists
WO2007099828A1 (ja) 2006-02-23 2007-09-07 Shionogi & Co., Ltd. 環式基で置換された含窒素複素環誘導体
CN101460161A (zh) * 2006-03-29 2009-06-17 弗尔德里克斯制药股份有限公司 α-突触核蛋白毒性的抑制
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
CA2670375A1 (en) * 2006-12-08 2008-06-12 F. Hoffmann-La Roche Ag Substituted pyrimidines and their use as jnk modulators
JO2642B1 (en) 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
KR20090116782A (ko) 2007-02-06 2009-11-11 베링거 인겔하임 인터내셔날 게엠베하 바이사이클릭 헤테로사이클, 당해 화합물을 함유하는 약물, 이의 용도 및 이의 제조방법
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
CN101663292A (zh) * 2007-04-23 2010-03-03 詹森药业有限公司 作为快速解离的多巴胺2受体拮抗剂的4-烷氧基哒嗪衍生物
ES2400710T3 (es) 2007-04-23 2013-04-11 Janssen Pharmaceutica, N.V. Tia(dia)zoles como antagonistas del receptor de dopamina 2 de disociación rápida
JP4691669B2 (ja) * 2007-08-22 2011-06-01 アストラゼネカ・アクチエボラーグ シクロプロピルアミド誘導体
WO2009058261A1 (en) * 2007-10-31 2009-05-07 Merck & Co., Inc. Modulation of sleep with nr2b receptor antagonists
ME01461B (me) 2008-02-07 2014-04-20 Boehringer Ingelheim Int Spirociklični heterocikli, ljekovi koji sadrže navedeno jedinjenje, njihova primjena i postupak za njihovu proizvodnju.
WO2009138781A1 (en) 2008-05-13 2009-11-19 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy}quinazoline
WO2010000456A1 (en) 2008-07-03 2010-01-07 Janssen Pharmaceutica Nv Substituted 6- (1-piperazinyl) -pyridazines as 5-ht6 receptor antagonists
KR101609218B1 (ko) 2008-07-31 2016-04-05 얀센 파마슈티카 엔.브이. 속해리성 도파민 2 수용체 길항제로서의 피페라진-1-일-트리플루오로메틸-치환된-피리딘
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
TW201039825A (en) * 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
US8389536B2 (en) 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
TWI520945B (zh) * 2010-02-18 2016-02-11 阿斯特捷利康公司 環丙基苯甲醯胺衍生物之新穎結晶形式
CN103140481A (zh) * 2010-02-18 2013-06-05 阿斯利康(瑞典)有限公司 包含环丙基酰胺衍生物的固体形式
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
ES2571741T3 (es) * 2011-03-31 2016-05-26 Bayer Ip Gmbh Bencimidazoles sustituidos como inhibidores de Mps-1 quinasa
EP2760856B1 (de) * 2011-09-30 2016-09-14 Bristol-Myers Squibb Company Selektive nr2b-antagonisten
WO2013156614A1 (en) 2012-04-20 2013-10-24 Ucb Pharma S.A. Methods for treating parkinson's disease
JP2016028017A (ja) * 2012-12-13 2016-02-25 大正製薬株式会社 フッ素置換ピペリジン化合物
JP2017001954A (ja) * 2013-11-08 2017-01-05 石原産業株式会社 含窒素飽和複素環化合物
EP3150598B1 (de) * 2014-05-28 2019-02-13 TOA Eiyo Ltd. Substituierte tropanderivate
JP2017516836A (ja) * 2014-06-04 2017-06-22 リューゲン ホールディングス （ケイマン） リミテッド Ｎｒ２ｂｎｍｄａ受容体アンタゴニストとしてのジフルオロエチルピリジン誘導体
AU2015317886A1 (en) 2014-09-15 2017-03-09 Rugen Holdings (Cayman) Limited Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists
WO2016100349A2 (en) * 2014-12-16 2016-06-23 Rugen Holdings (Cayman) Limited Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists
US10221182B2 (en) 2015-02-04 2019-03-05 Rugen Holdings (Cayman) Limited 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists
MX2017014287A (es) 2015-05-11 2018-03-07 Basf Se Proceso para preparar 4-amino-piridazinas.
JP6876625B2 (ja) 2015-06-01 2021-05-26 リューゲン ホールディングス （ケイマン） リミテッド Ｎｒ２ｂｎｍｄａレセプターアンタゴニストとしての３，３−ジフルオロピペリジンカルバメート複素環式化合物
EP3544610A1 (de) 2016-11-22 2019-10-02 Rugen Holdings (Cayman) Limited Behandlung von autistischen erkrankungen, zwangsneurosen und angststörungen
JP7301862B2 (ja) * 2018-02-23 2023-07-03 フラウンホーファー－ゲゼルシャフト ツル フェルデルング デル アンゲヴァンテン フォルシュング エー ファウ 歯周病及び関連疾患の治療に用いる細菌性グルタミニルシクラーゼの新規阻害剤

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL265777A (de) 1960-06-09
DE2341965C3 (de) * 1973-08-20 1979-01-25 C.H. Boehringer Sohn, 6507 Ingelheim 4- [N- (o-PyridyD- N-acyl] -aminolphenäthylpiperidine, Verfahren zu deren Herstellung sowie deren Verwendung bei der Bekämpfung von Schmerzzuständen
US4197304A (en) * 1975-09-23 1980-04-08 Janssen Pharmaceutica N.V. N-Aryl-N-(1-L-4-piperidinyl)-arylacetamides
WO1984001151A1 (en) * 1982-09-24 1984-03-29 Beecham Group Plc Amino-azabicycloalkyl derivatives as dopamine antagonists
WO1991012005A1 (en) 1990-02-06 1991-08-22 Pfizer Inc. Neuroprotective 3-piperidino-4-hydroxychroman derivatives and analogs
ES2146578T3 (es) 1990-05-10 2000-08-16 Pfizer Indolona neuroprotectora y derivados relacionados.
US5189036A (en) 1990-06-20 1993-02-23 Schering Ag Imidazolylbenzoyl substituted heterocycles
CZ390792A3 (en) 1991-04-18 1994-04-13 Pfizer Precursors of medicaments based on esters of phenolic 2-piperidino-1-alkanols, process of their preparation, intermediates and use
CZ284133B6 (cs) 1991-07-17 1998-08-12 Pfizer Inc. 2-/4-Hydroxypiperidino/-1-alkanolové deriváty jako antiischemická činidla. způsob jejich přípravy a použití.
MY110227A (en) 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
SI9300097B (en) * 1992-02-27 2001-12-31 Janssen Pharmaceutica Nv (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines
DK55192D0 (da) * 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
US5436255A (en) 1992-07-23 1995-07-25 Pfizer Inc. Method of treating diseases susceptable to treatment by blocking NMDA-receptors
DE4241632A1 (de) 1992-12-10 1994-06-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO1994014776A2 (en) 1992-12-21 1994-07-07 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
DE4304650A1 (de) 1993-02-16 1994-08-18 Thomae Gmbh Dr K Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
CA2157412A1 (en) 1993-03-03 1994-09-15 Julia Marie Heerding Balanoids
DE69413523T2 (de) 1993-03-18 1999-05-12 Merck Sharp & Dohme Ltd., Hoddesdon, Hertfordshire Benzimidazole derivate
WO1996002250A1 (en) 1994-07-20 1996-02-01 Acea Pharmaceuticals Inc. Haloperidol analogs and the use thereof
US5661161A (en) 1994-09-29 1997-08-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0742208A1 (de) 1995-05-05 1996-11-13 Grelan Pharmaceutical Co., Ltd. 2-Ureido-benzamid-Derivate
RU2176145C2 (ru) 1995-05-26 2001-11-27 Пфайзер Инк. Синергическое лечение паркинсонизма
EP0771779B1 (de) 1995-11-06 2002-05-02 Kuraray Co., Ltd. Verfahren zur Herstellung von Acetalen
DE19541264A1 (de) 1995-11-06 1997-05-07 Bayer Ag Purin-6-on-derivate
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
ZA9610745B (en) † 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
FR2744449B1 (fr) 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
EP0787493A1 (de) 1996-02-03 1997-08-06 F. Hoffmann-La Roche Ag Tetrahydroisochinolin-Derivate
TW504510B (en) * 1996-05-10 2002-10-01 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives
WO1997045119A1 (en) 1996-05-24 1997-12-04 Novartis Ag Use of substance p antagonists for treating social phobia
PT914605E (pt) 1996-07-25 2007-08-07 Biogen Idec Inc Modelo molecular para inibidores de vla-4
DZ2285A1 (fr) 1996-08-08 2002-12-25 Smithkline Beecham Corp Inhibiteurs de protéase de la cystéine.
EP0846683B1 (de) 1996-12-03 2001-09-19 F. Hoffmann-La Roche Ag 4-Hydroxypiperidinderivate
FR2758328B1 (fr) 1997-01-15 1999-04-02 Pf Medicament Nouvelles amines aromatiques derivees d'amines cycliques utiles comme medicaments
FR2758327B1 (fr) 1997-01-15 1999-04-02 Pf Medicament Nouvelles arylpiperazines derivees de piperidine
IT1291569B1 (it) 1997-04-15 1999-01-11 Angelini Ricerche Spa Indazolammidi come agenti serotoninergici
US6020347A (en) 1997-11-18 2000-02-01 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
WO1999025685A1 (en) 1997-11-18 1999-05-27 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
DE19815026A1 (de) * 1998-04-03 1999-10-07 Hoechst Schering Agrevo Gmbh Substituierte Piperidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
PE20000728A1 (es) 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
ATE279407T1 (de) 1998-08-07 2004-10-15 Applied Research Systems Fsh mimetika zur behandlung von infertilität
DE19838300A1 (de) 1998-08-24 2000-03-02 Bayer Ag 9-Dialkylaminopurinon-derivate
US6303637B1 (en) 1998-10-30 2001-10-16 Merck & Co., Inc. Heterocyclic potassium channel inhibitors
CN1353706A (zh) 1999-04-13 2002-06-12 巴斯福股份公司 整合素受体配体
US6329380B1 (en) 1999-06-30 2001-12-11 Merck & Co., Inc. SRC kinase inhibitor compounds

Also Published As

Publication number Publication date
PL364625A1 (en) 2004-12-13
KR20030076703A (ko) 2003-09-26
EP1379520B1 (de) 2006-04-26
EA005974B1 (ru) 2005-08-25
NZ527365A (en) 2005-08-26
HRP20030669A2 (en) 2005-06-30
EA200300919A1 (ru) 2004-02-26
WO2002068409A1 (en) 2002-09-06
NO20033732D0 (no) 2003-08-22
SK10542003A3 (sk) 2004-03-02
SI1379520T1 (sl) 2006-08-31
GEP20063741B (en) 2006-02-10
ZA200306159B (en) 2004-07-05
CA2438895A1 (en) 2002-09-06
MXPA03007621A (es) 2003-12-04
CN1503793A (zh) 2004-06-09
BR0207526A (pt) 2004-03-09
JP2004524314A (ja) 2004-08-12
US20020165241A1 (en) 2002-11-07
US7053089B2 (en) 2006-05-30
AU2002252053B2 (en) 2006-09-14
JP4179879B2 (ja) 2008-11-12
PT1379520E (pt) 2006-08-31
HUP0303258A3 (en) 2004-06-28
DE60210944D1 (de) 2006-06-01
IL157254A (en) 2008-11-26
KR100849839B1 (ko) 2008-08-01
AU2002252053C1 (en) 2002-09-12
DK1379520T3 (da) 2006-08-21
CN100567293C (zh) 2009-12-09
EP1379520B2 (de) 2014-04-09
ES2261658T3 (es) 2006-11-16
HUP0303258A2 (hu) 2004-01-28
DE60210944T3 (de) 2015-07-23
US7217716B2 (en) 2007-05-15
NO20033732L (no) 2003-10-22
DE60210944T2 (de) 2007-04-19
US20040209889A1 (en) 2004-10-21
BG108113A (bg) 2005-04-30
IS6902A (is) 2003-07-31
YU64303A (sh) 2006-05-25
ATE324371T1 (de) 2006-05-15
IL157254A0 (en) 2004-02-19
ECSP034744A (es) 2003-10-28
EP1379520A1 (de) 2004-01-14
CZ20032258A3 (cs) 2004-01-14
EE200300403A (et) 2003-12-15

Similar Documents

Publication Publication Date Title
UA75392C2 (en) N-substituted non-aryl heterocyclic antagonists nmda/nr2b
EP3166608B1 (de) Aminopyridazinonverbindungen als proteinkinasehemmer
JP6462842B2 (ja) ピリジニルトリアゾロン誘導体及び縮合ピリジニルトリアゾロン誘導体
CA3161278A1 (en) Sos1 inhibitors
KR101152719B1 (ko) 피리미딘 유도체
JP2024020220A (ja) 免疫調節剤としての複素環式化合物
AU2002252053A1 (en) N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists
TW200838517A (en) Compounds useful as protein kinases inhibitors
US9856262B2 (en) Analogues of 4H-pyrazolo[1,5-a] benzimidazole compound as PARP inhibitors
ES2686747T3 (es) Derivados de 4,5,6,7-tetrahidro-pirazolo[1,5-a]pirimidina y derivados de 2,3-dihidro-1H-imidazo[1,2-b]pirazol sustituidos como inhibidores de ROS1
JP7213193B2 (ja) Ｎｉｋ阻害剤としての新規の置換アザインドリン誘導体
EP4209485A1 (de) Verbindung mit antitumoraktivität und verwendung davon
AU2022271927A1 (en) Compound having anti-tumor activity and use thereof
CA3082509A1 (en) Pyrazolopyridinone compounds